Porter Alliance for Innovative Medicines is governed by a joint steering committee comprising equal representation from Deerfield and Stanford University. Stanford researchers are encouraged to submit proposals for consideration for execution through the collaboration. Accepted proposals will receive a development plan aimed at achieving Investigational New Drug (IND) readiness. Selected proposals will also have the eligibility for additional capital investments to create spin-off companies.
